
Morgan Stanley Upgrades Galderma, Citing Bullish Outlook for Nemluvio Drug
Analysts at Morgan Stanley raised their rating on the Swiss dermatology firm to “overweight,” citing a significantly improved sales forecast for its key drug Nemluvio and strong performance in its injectable aesthetics business.







